CLRB

Cellectar Biosciences, Inc. [CLRB] Stock Forecast

Q: What is Cellectar Biosciences, Inc. stock symbol ?

Cellectar Biosciences, Inc. is a US stock, located in Florham park of Nj and trading under the symbol CLRB

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CLRB Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

Does not have any significance market cap ($14.81M)

Top 10 Correlated ETFs

CLRB

Top 10 Correlated Stocks

CLRB

In the News

01:32 24 Mar 2023 CLRB

Here's Why Cellectar Biosciences Shares Are Rising

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.

07:46 24 Mar 2023 CLRB

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

10:52 24 Mar 2023 CLRB

Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:32 24 Mar 2023 CLRB

Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO. Dr Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and collaborate with clinicians and scientists to advance the company's research programs.

12:27 24 Mar 2023 CLRB

Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer. Related: Cellectar Receives $2M NIH Grant For Rare Lymphoma Study.

04:01 24 Mar 2023 CLRB

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:

11:54 24 Mar 2023 CLRB

Cellectar Receives $2M NIH Grant For Rare Lymphoma Study

Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy.

08:30 24 Mar 2023 CLRB

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI).

08:30 24 Mar 2023 CLRB

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131)

08:30 24 Mar 2023 CLRB

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

CLRB Financial details

Company Rating

Neutral

Market Cap

14.81M

Income

-28.6M

Revenue

Book val./share

2.2

Cash/share

2.82

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 May 2023

P/E

-0.34

Forward P/E

PEG

-0.66

P/S

P/B

0.74

P/C

0.55

P/FCF

-0.66

Quick Ratio

2.73

Current Ratio

2.88

Debt / Equity

0.39

LT Debt / Equity

0.04

EPS (TTM)

-4.52

EPS next Y

EPS next Q

EPS this Y

-5.81%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-20.31%

SMA20

-4.94%

SMA50

-10.47%

SMA100

-23.38%

Inst Own

30.79%

Inst Trans

-69.21%

ROA

-141%

ROE

-117%

ROC

-2.13%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

9.74M

Shs Float

6.7M

Target Price

52W Range

1.25-7.9

52W High

-78%

52W Low

+54%

RSI

44.29

Rel Volume

0.14

Avg Volume

71.32K

Volume

9.64K

Perf Week

-2.53%

Perf Month

-11.19%

Perf Quarter

-54.17%

Perf Half Y

-65.85%

Beta

1.17152

Volatility

0.02%, 0.13%

Prev Close

2.33%

Price

1.54

Change

-1.28%

CLRB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-44.7	-18.36	-7.62	-4.35	-4.05
Operating cash flow per share	-38.63	-15.24	-7.03	-4.07	0
Free cash flow per share	-39.93	-15.27	-7.06	-4.09	-0.03
Cash per share	44.75	13.83	28.85	6.43	2.82
Book value per share	44.77	11.8	27.66	5.95	2.2
Tangible book value per share	44.77	11.8	27.66	5.95	2.2
Share holders equity per share	44.77	11.8	27.66	5.95	2.2
Interest debt per share	0.11	0.74	0.22	0.05	0.09
Market cap	4.59M	17.27M	41.21M	36.86M	12.07M
Enterprise value	-8.66M	7.18M	-15.53M	1.46M	-7.2M
P/E ratio	-0.35	-1.23	-2.73	-1.53	-0.42
Price to sales ratio	0	0	0	0	0
POCF ratio	-0.4	-1.48	-2.96	-1.63	0
PFCF ratio	-0.39	-1.47	-2.94	-1.62	-53.39
P/B Ratio	0.35	1.91	0.75	1.12	0.78
PTB ratio	0.35	1.91	0.75	1.12	0.78
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0.66	-0.52	1.04	-0.06	0.25
EV to operating cash flow	0.76	-0.61	1.11	-0.06	0
EV to free cash flow	0.73	-0.61	1.11	-0.06	31.85
Earnings yield	-2.88	-0.82	-0.37	-0.65	-2.37
Free cash flow yield	-2.58	-0.68	-0.34	-0.62	-0.02
Debt to equity	0.14	0.35	0.07	0.13	0.39
Debt to assets	0.12	0.26	0.07	0.11	0.28
Net debt to EBITDA	1.01	0.72	3.8	1.48	0.68
Current ratio	8.6	4.11	16.26	9.16	3.71
Interest coverage	-392.61	-331.96	-1.4K	-10.57K	0
Income quality	0.86	0.83	0.92	0.94	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0	0	0.01	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-4.68	-0.18	-0.44	-0.94	-1.52
Stock based compensation to revenue	0	0	0	0	0
Graham number	212.19	69.83	68.85	24.12	14.16
ROIC	0.97	1.38	0.27	0.68	1.58
Return on tangible assets	-0.88	-1.15	-0.26	-0.65	-1.32
Graham Net	38.7	9.67	26.9	5.68	1.95
Working capital	12.33M	8.62M	54.38M	32.58M	15M
Tangible asset value	13.26M	9.06M	54.79M	33.05M	15.51M
Net current asset value	12.16M	8.19M	54.07M	32.41M	14.45M
Invested capital	0	0.06	0.01	0.01	0.04
Average receivables	0	0	0	0	0
Average payables	306K	945K	1.35M	1.42M	707.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1	-1.56	-0.28	-0.73	-1.84
Capex per share	-1.3	-0.03	-0.03	-0.03	-0.03

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-0.99	-1	-1.22	-1.28	-1.02
Operating cash flow per share	-0.75	-0.82	-0.94	-1.15	0
Free cash flow per share	-0.78	-0.83	-0.95	-1.15	2.51
Cash per share	5.96	5.01	4.06	2.91	2.82
Book value per share	5.52	4.45	3.31	2.09	2.2
Tangible book value per share	5.52	4.45	3.31	2.09	2.2
Share holders equity per share	5.52	4.45	3.31	2.09	2.2
Interest debt per share	0.05	0.04	0.04	0.03	0.09
Market cap	39.75M	42.03M	24.67M	20.53M	12.07M
Enterprise value	4.35M	11.66M	103.17K	2.95M	-7.2M
P/E ratio	-1.68	-1.71	-0.83	-0.66	-0.42
Price to sales ratio	0	0	0	0	0
POCF ratio	-8.81	-8.34	-4.29	-2.93	0
PFCF ratio	-8.57	-8.29	-4.23	-2.92	0.68
P/B Ratio	1.2	1.54	1.22	1.61	0.78
PTB ratio	1.2	1.54	1.22	1.61	0.78
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-0.74	-1.91	-0.01	-0.38	0.99
EV to operating cash flow	-0.96	-2.31	-0.02	-0.42	0
EV to free cash flow	-0.94	-2.3	-0.02	-0.42	-0.41
Earnings yield	-0.15	-0.15	-0.3	-0.38	-0.6
Free cash flow yield	-0.12	-0.12	-0.24	-0.34	1.47
Debt to equity	0.13	0.18	0.28	0.52	0.39
Debt to assets	0.11	0.15	0.22	0.34	0.28
Net debt to EBITDA	6.02	4.98	3.32	2.26	2.66
Current ratio	9.16	6.75	4.51	2.88	3.71
Interest coverage	4.46K	-14.28K	-15.46K	-1.88K	0
Income quality	0.76	0.82	0.77	0.9	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0.01	0.01	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-3.3	-0.69	-2.09	-0.21	-3.09
Stock based compensation to revenue	0	0	0	0	0
Graham number	11.08	10.03	9.51	7.75	7.11
ROIC	0.17	0.21	0.31	0.48	0.41
Return on tangible assets	-0.16	-0.19	-0.29	-0.4	-0.33
Graham Net	5.27	4.23	3.13	1.84	1.95
Working capital	32.58M	26.74M	19.68M	12.25M	15M
Tangible asset value	33.05M	27.21M	20.19M	12.75M	15.51M
Net current asset value	32.41M	26.61M	19.59M	12.19M	14.45M
Invested capital	0.01	0.01	0.01	0.02	0.04
Average receivables	0	0	0	0	0
Average payables	707.5K	707.5K	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.18	-0.23	-0.37	-0.61	-0.47
Capex per share	-0.02	0	-0.01	0	-0.02

CLRB Frequently Asked Questions

What is Cellectar Biosciences, Inc. stock symbol ?

Cellectar Biosciences, Inc. is a US stock , located in Florham park of Nj and trading under the symbol CLRB

What is Cellectar Biosciences, Inc. stock quote today ?

Cellectar Biosciences, Inc. stock price is $1.54 today.

Is Cellectar Biosciences, Inc. stock public?

Yes, Cellectar Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 71.32K
Market Capitalization 14.81M
Employee 12
CEO Mr. James V. Caruso
Headquarters Florham Park,NJ,US
IPO Date 2005-05-20
Website https://www.cellectar.com

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.